Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-07-20

FDA Approved: SUMATRIPTAN AND NAPROXEN SODIUM — Original Application (NorthStar RxLLC)

View source ↗

Summary

The FDA approved a generic fixed-dose combination of sumatriptan and naproxen sodium for the acute treatment of migraine, under an original application by North…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SUMATRIPTAN AND NAPROXEN SODIUM (Sumatriptan and Naproxen Sodium)

Snippet

ORIG AP for SUMATRIPTAN AND NAPROXEN SODIUM (SUMATRIPTAN AND NAPROXEN SODIUM)